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Abstract: The effect of eugenol on colchicine transport across an isolated rat intestinal 
membrane was studied using an in vitro diffusion chamber system. We found that eugenol 
increased the absorptive transport of the drug efficiently. The effect of eugenol on intestinal 
absorption of colchicine in an oral administrative nanoemulsion formulation was also 
demonstrated in vivo. The colchicine nanoemulsion was prepared with isopropyl myristate, 
eugenol, Tween80, ethanol and water, and eugenol was used as an oil phase in the formulation; 
an average particle size of this nanoemulsion was 41.2 ± 7.2 nm. The permeation of 
colchicine in the nanoemulsion across the intestinal membrane was significantly different 
from that of the control group (0.2 mM   colchicine). Finally, co-administration of eugenol in 
colchicine nanoemulsion to enhance the colchicine bioavailability was investigated by an oral 
administration method. After oral administration of colchicine (8 mg/kg) in the form of either 
the nanoemulsion or in free colchicine solution, the relative bioavailability of nanoemulsion and 
eugenol–nanoemulsion were enhanced by about 1.6- and 2.1-fold, respectively, compared with 
free colchicine solution. The procedure indicated that the intestinal absorption of colchicine 
was enhanced significantly by eugenol in the tested nanoemulsion. All the results suggested 
that eugenol is an efficient component in an oral administrative formulation for improving the 
intestinal absorption of colchicine.
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Introduction
Oral administration of drugs is a preferred route by virtue of convenience and 
  compliance. However, the delivery of some drugs by the oral route is considered to be 
a challenge due to the poor water solubility, poor permeability, and rapid metabolism. 
To achieve oral delivery of drugs with poor solubility and poor permeability properties, 
many strategies have been developed to improve bioavailability, such as using 
absorption enhancers, and developing new pharmaceutical excipients1–3 and novel 
dosage forms, such as nanoemulsion.4,5 Several pharmaceutical excipients have been 
shown to reduce the efflux function of permeability glycoprotein (P-gp) in the intestine, 
and hence increase the absorption of drugs which act as P-gp substrates.6–10
Some terpenoids were recently reported as P-gp substrates or inhibitors,11–13 and 
Yoshida et al found that natural products containing terpenoids may inhibit P-gp-mediated 
transport.14,15 Eugenol is a simple monocyclic terpene, which has been reported as a 
penetration enhancer in the transdermal drug delivery system.16,17 Furthermore, eugenol 
could increase the sensitivity of Hep G2 cells to anti-cancer drugs, accompanied by a 
reduction in the expression of multidrug resistance protein 2 (MRP2).18 There are few International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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reports, however, on the use of eugenol in oral administration 
formulations to enhance bioavailability of poor permeability 
drugs.
P-glycoprotein can transport colchicine and expel it from 
the cell, preventing intracellular penetration and   causing 
resistance to treatment. The key colchicine targets may 
explain the wide interindividual variations in responses to 
the drug. When inhibitors or modulators are prescribed in 
combination, changes in P-glycoprotein activity may lead to 
intracellular accumulation of colchicine.19
In this paper, the effects of eugenol on the intestinal trans-
portation and absorption of colchicine have been demonstrated 
in vitro. An oral administrative nanoemulsion of colchicine 
was also prepared using eugenol as the oil phase. The effect 
of eugenol in this nanoemulsion formulation was investigated 
in vitro and in vivo, and the improvement of colchicine bio-
availability by addition of eugenol was confirmed.
Materials and methods
Materials
Colchicine was purchased from Shanghai Chemical Reagents 
Institute (Shanghai, China). Eugenol was bought from 
Feixiang Chemical Industries, Ltd (Shanghai, China). All 
other reagents were of analytical grade.
Preparation of drug solution
Colchicine was dissolved in pH 7.4 Tris-HEPES buffer 
solution to yield a final concentration, 0.2 mM colchicine 
was used for the in vitro transport study, while 8 mg/kg of 
colchicine was used for an in vivo absorption study. In some 
experiments, 0.5 to 2% (w/w) of eugenol was added to the 
donor solution.
Nanoemulsion preparation
A pseudo-ternary phase diagram was constructed to identify the 
formation of nanoemulsion. The nanoemulsion of colchicine 
was prepared by solubilization of colchicine in ethanol, which 
was used as co-surfactant. The oil phase (isopropyl myristate), 
eugenol, and surfactant (Tween80) were added slowly under 
gentle stirring until a homogeneous mixture formed. Then water 
was added dropwise at 37°C under stirring at 600 rpm.
Nanoemulsion droplet size analysis and 
morphology observation by transmission 
electron microscope (TeM)
The particle size of the nanoemulsion was determined 
by a photo correlation spectroscopy instrument (Malvern 
Instruments, Malvern, UK) at 25°C. The morphology of the 
droplet was observed using transmission electron microscopy 
(JEM-2010; JEOL, Tokyo Japan). One drop of diluted 
samples was deposited on a film-coated 200-mesh copper 
specimen grid and allowed to stand for 10 minutes after 
which any excess fluid was removed with filter paper. The 
grid was then stained with one drop of 3% phosphotungstic 
acid and allowed to dry for 5 minutes before examination 
with an electron microscope.
In vitro transport of colchicine
The transport of colchicine across a rat intestinal   membrane 
was studied with the diffusion chamber.20,21 Male Sprague-
Dawley rats, weighing 250 to 300 g, were fasted   overnight. 
The experimental procedures in this article were in accordance 
with the guidelines of the Animal Ethics   Committee at 
  Shanghai Jiao Tong University.
The intestine was exposed through a midline abdominal 
incision, removed, and washed in ice-cold saline. Intestinal seg-
ments, excluding Peyer’s patches, were isolated and immersed 
in ice-cold Tris-HEPES buffer solution (pH 7.4) containing 
25 mM HEPES, 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 
0.8 mM MgSO4, 5 mM glucose, and 1 M Tris solution. Seg-
ments were cut open and the intestinal sheets were mounted 
onto the pins of the cell, and the half-cells were clamped 
together. Drug solution (7 mL) of 0.2 mM colchicine (con-
trol), or 0.2 mM colchicine with eugenol, nanoemulsion, and 
eugenol–nanoemulsion, was added to the donor site, respec-
tively, whereas the same volume of drug-free buffer was added 
to the opposite side. The temperature of intestinal membranes 
was maintained at 37°C, and both fluids were circulated by gas 
lift with 95%O2/5%CO2. During the transport studies, aliquots 
were taken from the receptor chamber at predetermined times 
up to 2 hours. The receptor chamber samples were replaced 
with an equal volume of appropriate buffer. The permeated 
drugs were assayed using HPLC. The apparent permeability 
coefficients (Papp) of drugs were calculated from the slope of 
the linear portion of permeability-time profiles of drugs by 
the relationship: Papp = (dXR/dt) × (1/A ⋅ C0) p 1/60, where Papp 
is the apparent permeability coefficient, XR is the amount of 
drug in the receptor side, A is the diffusion area, and C0 is the 
initial concentration of drug in the donor side.
The absorption enhancement ratio (R) was calculated 
from Papp values from the mucosal to the serosal side as 
follows:
R = Papp (sample)/Papp (control)
The efflux ratio was used to evaluate the extent of efflux,22–25 
which was defined as follows:International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Efflux ratio = Pappsm/Pappms
where Pappsm is the average of the permeability coefficient 
from the serosal to the mucosal side and Pappms is the 
  average of the permeability coefficient from the mucosal to 
the serosal side.
In order to confirm whether the viability of the intestinal 
membrane was maintained during the transport studies, the 
transport of trypan blue dye was examined. 1% of trypan blue 
solution was added to the mucosal side and the transport of 
this dye across the rat intestinal membrane was monitored 
for 2 hours by an in vitro diffusion chamber method. There 
was no transport of the dye, confirming that the viability of 
the intestinal membranes was maintained during the transport 
experiments.
Pharmacokinetic study
Male Sprague-Dawley rats were fasted overnight with free 
access to water before drug administration. The experiments 
were carried out in accordance with the guidelines of Animal 
Ethics Committee at Shanghai Jiao Tong University. Free 
colchicine solution as a control sample, the nanoemulsion 
formulation (present and absent eugenol), and the control 
sample were administered orally (8 mg/kg of colchicine) with a 
blunt needle via the esophagus into the stomach. Subsequently, 
blood samples (200 µL) were collected into heparinized micro-
centrifuge tubes from the caudal vein at a designated time. 
Blood samples were centrifuged for 5 minutes at 5000 × g and 
the concentrations of colchicine in the plasma were determined 
by HPLC (see Analysis of drug concentration). The area under 
the plasma concentration time curve (AUC) from time zero 
to final sampling time (8 hours) was calculated by the linear 
trapezoidal rule. The peak plasma concentration (Cmax) and 
the time to reach the peak plasma concentration (Tmax) were 
observed values from the experimental data.
Analysis of drug concentration
Samples obtained from in vivo absorption studies were 
assayed on a reversed-phase HPLC system containing 5 µm 
Cosmosil (4.6 mm × 15 cm) particles in an analytical   column 
from Dikama Technologies, a Shimadzu LC-20A pump 
system, a Shimadzu LC-20A autoinjector, and a SPD-20A 
UV-VIS detector. The mobile phase for colchicine analysis 
was 0.05 mol/L potassium dihydrogen phosphate solution 
(pH 5.5):methanol = 55:45. The flow rate was 1.0 mL minute−1. 
The concentrations of colchicine were determined using a UV 
detector (Shimadzu LC-20A) at 350 nm wavelengths.
When the concentrations of colchicine in plasma were 
determined, 400 µL acetonitrile were added to 0.1 mL of the 
plasma samples. These were then mixed using a vortex mixer 
and centrifuged at 3000 rpm for 5 minutes. The supernatant 
was transferred to a clean test tube and evaporated in a 
  centrifugal evaporator at 40°C, the residue was then   dissolved 
in a mobile phase solution, and the solution (20 µL) was 
injected into the HPLC for analysis.
Statistics
Results are expressed as the mean of SD of at least three 
experiments. Statistical significance was assessed using 
Student’s t-test or Dunnett’s test for multiple comparisons 
with P , 0.05 as the minimal level of significance.
Results
characteristics and physicochemical 
properties of colchicine nanoemulsion
The ternary phase diagrams of a system containing isopropyl 
myristate, eugenol, Tween80, ethanol, and distilled water 
are shown in Figure 1. A transparent nanoemulsion existed 
in the area. An optimal nanoemulsion was composed of 5% 
isopropyl myristate/eugenol (w/w, 3/2), 30% Tween80 and 
10% ethanol (surfactant/cosurfactant ratios, km = 3), and 55% 
of aqueous solution (w/w). The nanoemulsion was stable at 
room temperature and phase separation did not occur.
Particle size of nanoemulsion was one of the most 
important properties. As a result, the average droplet size 
of the colchicine nanoemulsion was 41.2 nm±7.2. The 
morphology of colchicine nanoemulsion was characterized 
using TEM (Figure 2). It showed a spherical shape and uni-
form droplet size of nanoemulsion. Samples were diluted 
with distilled water before testing to avoid multiscattering. 
After that, the droplet size of the diluted nanoemulsion was 
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Figure  1  The  ternary  phase  diagram  of  the  colchicine  nanoemulsion  system 
containing Tween80, ethanol, distilled water and isopropyl myristate (IPM), eugenol 
as surfactant, water, and oil system. The shaded areas in the phase diagram represent 
clear and transparent nanoemulsions.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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not significantly changed. The mean particle size remained 
consistent up to 3 months at room temperature.
effects of various concentrations of 
eugenol on the permeability of colchicine 
across the intestinal membranes
Figure 3 shows the effects of various concentrations of 
eugenol on the absorptive transport of colchicine in the rat 
jejunal membranes. The absorptive transport of colchicine 
was gradually increased as the concentration of eugenol 
increased, and the absorptive transport of colchicine was 
enhanced by the addition of eugenol at concentrations over 
the range of 0.5% to 2% (w/w).
effects of nanoemulsions incorporating 
eugenol on the permeability of colchicine 
across the intestinal membranes
Figure 4 shows the effect of eugenol incorporated nanoemul-
sion on the absorptive and secretory transport of colchicine 
in the rat jejunal membranes.
The absorptive transport of colchicine was enhanced by the 
nanoemulsion and eugenol incorporated   nanoemulsion, which 
from each formulation was in the following order: eugenol nanoe-
mulsion . eugenol . nanoemulsion without eugenol .   control 
group (colchicine solution). The secretory transport of 
colchicine nanoemulsion decreased compared with the control. 
The order was: eugenol nanoemulsion . eugenol . nanoemul-
sion without eugenol . control group (colchicine solution).
The Papp values of colchicine from mucosal to serosal 
and serosal to mucosal efflux were compared and results are 
shown in Table 1. The results show that the permeability 
coefficient of the eugenol, nanoemulsion, and eugenol–
nanoemulsion was significantly higher than that of the control 
in the mucosal to serosal transport. In particular, the Papp 
values of colchicine from eugenol–nanoemulsion was around 
2.76 times higher than that from the control group.
Table 1 also shows that the serosal to mucosal transport, 
the permeability coefficient of eugenol, and eugenol–
nanoemulsion significantly decreased compared with the 
control. For the control, the serosal to mucosal permeability 
coefficient was higher than that of mucosal to serosal value, 
indicating that colchicine is a substrate of P-gp.
effect of nanoemulsions incorporating 
eugenol on the intestinal absorption 
of colchicine by an in vivo oral 
administration method
Finally, the effect of eugenol on the intestinal absorption 
of colchicine was examined by in vivo absorption studies. 
Therefore, a solution containing colchicine and colchicine 
nanoemulsion which incorporated eugenol were administered 
orally, respectively, with a blunt needle via the esophagus 
into stomach.
Figure 5 shows plasma concentration-time profiles of 
colchicine after the oral administration of colchicine   solution 
and colchicine nanoemulsion. A significant increase in 
the AUC of colchicine was observed when the colchicine 
nanoemulsion was orally administered. Table 2 shows the 
pharmacokinetic parameters (Cmax, Tmax, and AUC0–8h) of 
colchicine after its oral administration. We observed a 
significant increase in Cmax and AUC0–8h values after oral 
administration of colchicine in eugenol nanoemulsion. These 
findings suggest that eugenol might be a useful excipient for 
improving the intestinal absorption of colchicine.
Discussion
The present study demonstrated that eugenol could 
increase the absorptive transport of colchicines, and could 
Figure 2 Transmission electron microphotograph of colchicine nanoemulsion.
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decrease the secretory transport in the intestine. The 
efflux ratio of colchicine was apparently reduced in the 
presence of eugenol compared with the control. Previous 
studies indicated that the secretory direction transport of 
colchicine was inhibited in the presence of verapamil in 
intestinal membrane and Caco-2 cell.26 In addition, Dahan 
and Amidon reported that the secretion of colchicine was 
significantly inhibited and its absorption was significantly 
enhanced by several P-gp substrates including verapamil 
and quinidine in Caco-2 cell.
In the present study, we found that eugenol could increase 
the absorptive transport of colchicine. However, the mecha-
nism in the intestine was not fully studied in this paper. 
Eugenol can be used as percutaneous absorption enhancer, 
as a result of lipid extraction and improvement in the parti-
tioning of the drug to the stratum corneum.16 Yoshida et al 
reported that some natural products containing terpenoids 
may inhibit P-gp-mediated transport and interact with P-gp 
substrates in the intestinal absorption process, and might 
decrease the expression of P-gp.15
Eugenol is not completely soluble in water, and 
was an oil excipient and enhancer in the nanoemulsion. 
Nanoemulsion systems are mixtures of oils, surfactants, 
co-surfactant, and water, which can produce nanoemulsions 
with a particle size ,100 nm, and are clear and transparent. 
Thus nanoemulsion systems can help solubilize eugenol 
and colchicine.
It was demonstrated that multidrug resistance protein 2 
(MRP2) is also involved in the efflux process of colchicine27 
and that eugenol could reduce the expression of MRP2.18 
Therefore eugenol may play a potential role in the effects of 
MRP2 on the efflux of colchicine.
Another possibility to way of increasing the transport of 
colchicine across the intestinal membrane in the   presence of 
eugenol is that this excipient might loosen the tight junction 
of the epithelium, thereby increasing the transport of drugs 
via a paracellular pathway. Chitosan-4 thiobutylamidine/ 
glutathione (Ch-TBA/GSH) can significantly increase 
the intestinal absorption and oral bioavailability of 
rhodamine123, a P-gp substrate, of which a possible reason 
is opening the tight junctions.6
Investigating the intestinal absorption is important, not 
only by in vitro studies but also by in vivo studies, which 
evaluate how pharmaceutical excipients improve the intes-
tinal absorption of P-gp substrates. Bittner et al reported 
that a commonly used surfactant, vitamin E-TPGS, and 
solutol HS15 could improve the intestinal absorption of 
colchicine after oral administration in rats.28 In the pres-
ent study, therefore, colchicine was selected as a model 
of P-gp substrate and we examined intestinal absorption 
25
20
15
10
5
0
02 04 06 08 0 100 120 140 02 04 06 08 0 100 120 140
Time (h) Time (min)
Control, S-M
NE, S-M
Eugenol-NE, S-M
Eugenol, S-M
Control, S-M
NE, S-M
Eugenol-NE, S-M
Eugenol, S-M
20
15
10
5
0
C
u
m
u
l
a
t
i
v
e
 
a
m
o
u
n
t
 
(
n
m
o
l
)
C
u
m
u
l
a
t
i
v
e
 
a
m
o
u
n
t
 
(
n
m
o
l
)
Absorptive (M to S) transport Secretory (S to M) transport
Figure 4 Time course of absorptive (mucosal to serosal, M to S) and secretory (S to M) transport of colchicine across the rat jejunal membrane in the presence of 2% eugenol 
(w/w), nanoemulsion (Ne) and eugenol–nanoemulsion (eugenol–Ne). results are expressed as the mean±SD of at least three experiments.
Table 1 effects of eugenol and nanoemulsion (Ne) on the permeability of colchicine across the intestinal jejunal membranes
Excipient Papp (×10−6 cm/s) Absorption  
enhancement ratio: R
Efflux ratio
M to S S to M
control 1.34±0.28 4.81±0.26 1 3.59
2% eugenol 3.13±0.15* 3.07±0.12** 2.33 0.98
Nanoemulsion 2.12±0.32* 3.43±0.47* 1.58 1.62
eugenol–Ne 3.70±0.37** 2.86±0.19** 2.76 0.77
Notes: each value represents the mean ± SD of at least three experiments; *P , 0.05; **P , 0.01, compared with control.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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of colchicine in the presence or absence of eugenol by the 
in vivo method.
As shown in Figure 5, we found a significant increase in 
Cmax and AUC0–8h values after administration of colchicine 
with eugenol incorporated in nanoemulsion. We previously 
demonstrated that PEG20,000 could increase the intestinal 
absorption of rhodamine123 by the in situ closed-loop 
  method.9 Therefore, it can be suggested that eugenol might 
have a potential role in intestinal P-gp, and could increase the 
absorption of colchicine from the small intestine, although 
we have no direct evidence to support these mechanisms at 
present. Tmax was obtained from the experimental measure-
ments; the eugenol–NE Tmax of colchicine occurs later than 
that of the control, the reason for which can be speculated 
as the process of drug release from the nanoemulsion. 
According to the references, many formulations have similar 
reactions.29–31
Nanoemulsion is a lipid-based delivery system, and 
has some advantages including high solubilization, ther-
modynamic stability, and surfactant-induced permeability 
enhancement.32,33 The nanoemulsion system is considered to 
be an alternative for the oral delivery of some drugs, such as 
nitrendipine, ibuprofen, and docetaxel. Therefore employ-
ing the nanoemulsion formulation can improve their oral 
bioavailability.4,5,34
A number of studies have been conducted to increase the 
poor absorption of some drugs using the co-  administration 
of enhancers. Hirunpanich’s studies indicated that 
ethyl   docosahexaenoate, which was incorporated into 
a nanoemulsion formulation as an oil ingredient,35 can 
improve the oral   bioavailability of cyclosporine A. Our study 
  demonstrated that eugenol, incorporated into a nanoemulsion, 
could also enhance the permeation and oral bioavailability 
of colchicine. Therefore, based on these findings, our pres-
ent study was well correlated with studies by Hirunpanich 
and Sato.35
Although studies have investigated how the eugenol–
nanoemulsion drug delivery system can enhance permeation 
and oral bioavailability, the therapeutic potential of this 
delivery system and the possibilities of applying eugenol 
as a pharmaceutical excipient need further research in the 
future.
Conclusion
In conclusion, eugenol could improve the intestinal 
absorption of drugs. The present investigation also devel-
oped a novel nanoemulsion formulation of eugenol as an 
oil ingredient and demonstrated that eugenol–nanoemulsion 
exhibited a higher bioavailability of colchicine than the 
control group. Thus, eugenol in oral drug formulations 
might be useful for improving the intestinal absorption of 
P-gp substrates including colchicine or as an excipient of 
nanoemulsions.
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